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Abstract: Group cognitive–behavioral therapy (GCBT) may be a cost-effective alternative 
modality for the treatment of obsessive–compulsive disorder (OCD). In the last decade, a great 
deal of research has been conducted to evaluate the efficacy of GCBT for OCD. Despite prom-
ising results, studies have produced inconclusive evidence. The current paper will present a 
protocol for a systematic review and meta-analysis of randomized controlled trials assessing 
the efficacy of GCBT compared with control conditions or individual CBT at post-treatment 
and follow-up on OCD symptoms, anxiety, depression, obsessive beliefs, quality of life, and 
functioning. Another aim will be to compare the levels of early drop out from GCBT relative 
to control conditions or individual CBT. Finally, the study will investigate potential outcome 
moderators (age, sex, OCD severity, severity of concurrent depression, comorbid personality 
disorders, duration of OCD symptom onset, duration of treatment, intensity of treatment, gen-
eration cohort, methodological quality, and publication date). A systematic review following the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines 
will be conducted using random-effects meta-analyses. Online databases and trial registries 
will be searched, the corresponding authors will be contacted, and conference proceedings and 
relevant journals will be hand-searched to locate published and unpublished studies. Risk of 
bias will be assessed using the Cochrane Collaboration’s tool.
Keywords: obsessive–compulsive disorder, cognitive–behavioral therapy, meta-analysis, group 
therapy
Introduction 
Obsessive–compulsive disorder (OCD) is a chronic psychological condition with a life-
time prevalence of 2% in the general population.1 OCD consists of intrusive thoughts, 
impulses or mental images, and repetitive behaviors or mental compulsions, which can 
strongly affect the quality of life of the individual.2 The World Health Organization 
has ranked OCD as the tenth leading cause of disability of all health conditions in the 
industrialized world.3
Several well-controlled studies demonstrated that cognitive–behavioral therapy 
(CBT) with exposure and response prevention (ERP) is the most effective psycho-
logical treatment for OCD.4 ERP entails confrontation with obsessional stimuli and 
refraining from compulsions to demonstrate that feared consequences will not occur.4 
Improvement in OCD symptoms is mediated by habituation of anxiety response and a 
reduction in exaggerated probabilities associated with feared consequences as a result 
of repeated disconfirmation of the expected harm.5
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Research suggests that individual CBT for OCD produces 
statistically significant improvements in approximately 75% 
of patients.5 However, when the reliable change criterion is 
used, only 25% of cases do achieve a full recovery status.5 
Moreover, ERP is associated with a 25% refusal rate, even 
in clinical trials in which treatment is offered at no cost,6 
presumably due to the apprehension about the time, effort, 
or perceived distress associated with the treatment. The 
importance of tailored treatment approaches with the aim 
of targeting frequent relapses in OCD patients was also put 
forward.6 However, only few patients receive ERP,7 and access 
to psychotherapy is limited by the high costs of individual 
sessions and long waiting lists.8,9
Group (G)CBT may be a cost-effective modality of 
treatment. In the last decade, a great deal of research has 
been conducted to evaluate the efficacy of GCBT for OCD.10 
Despite promising results, studies have produced incon-
clusive evidence.11 To our knowledge, only one systematic 
review was conducted. Jónsson and Hougaard12 performed a 
meta-analysis of 13 studies, including randomized controlled 
trials (RCTs) and open trials, which compared GCBT ver-
sus waitlist control conditions. They reported a large mean 
pre–post effect size (Cohen’s d=1.18) and a large between-
groups effect size (Cohen’s d=1.13). However, the authors 
assessed the effects of GCBT versus control conditions 
exclusively on OCD symptoms as outcomes, and they did 
not examine therapeutic gains at follow-up. In addition, 
due to the limited number of studies (one trial), the authors 
did not conduct a meta-analysis directly comparing GCBT 
versus individual CBT.
To date, a systematic review including only RCTs and 
assessing GCBT relative to control conditions or individual 
CBT does not exist. Therefore, the current paper will present 
a protocol for a systematic review and meta-analysis of RCTs. 
The research will aim to assess the following:
1. the efficacy of GCBT compared with control conditions 
(waitlist or active control conditions) at post-treatment 
and follow-up on OCD symptoms, anxiety, depres-
sion, obsessive beliefs, quality of life, and functioning; 
follow-up assessments ranging from 1 to 6 months will 
be pooled to evaluate the maintenance of treatment gains 
at midterm follow-up; and follow-up assessments longer 
than 6 months will be pooled to evaluate the maintenance 
of treatment gains at long-term follow-up;
2. the efficacy of GCBT compared with individual CBT on 
the aforementioned outcomes;
3. to examine levels of early dropout from GCBT relative 
to control conditions or individual CBT; and
4. to investigate potential outcome moderators (age, sex, 
OCD severity, severity of concurrent depression, comor-
bid personality disorders, duration of OCD symptoms, 
duration of treatment, intensity of treatment, concurrent 
pharmacological treatments, generational cohort coded 
as adult samples and children/adolescent samples, meth-
odological quality, and publication date).
Methods/design
Eligibility criteria
According to the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) guidelines,13 the 
criteria considered for inclusion of the studies will involve 
the following characteristics: 1) participants; 2) interventions; 
3) comparators; 4) outcomes; and 5) study/design.
characteristics of participants
Studies will be included if they were conducted on patients 
with a primary diagnosis of OCD, and if the diagnosis was 
made through a semistructured interview based on stan-
dardized diagnostic criteria, such as the Structured Clinical 
Interview for the Diagnostic and Statistical Manual of Mental 
Disorders, 4th Edition (DSM-IV) (SCID-I).14 Studies will be 
included if they involved only patients with a current primary 
diagnosis of OCD. Studies will be included if they used either 
adult or adolescent/children samples. Diagnoses of comorbid 
disorders considered as exclusion criteria will have to be 
made through structured interviews as well. Studies on pri-
mary compulsive hoarding will be excluded. The main reason 
for this is that the treatment for hoarding differs from CBT 
for OCD, and hoarding is a separate diagnosis in the DSM-5.2 
Studies where all the patients had OCD and a specific comor-
bid psychological or medical disorder (eg, comorbid major 
depressive disorder) will be excluded. Studies where all the 
participants had a comorbid mood/anxiety disorder will be 
excluded since these studies could use a special population 
of patients with OCD (ie, all the patients have OCD and 
comorbid generalized anxiety disorder) who are believed to 
have clinical characteristics different from those of patients 
with OCD alone. Thus, studies where only some patients had 
a comorbid disorder will be included since co-occurrence of 
other disorders is relatively common in OCD. In addition, 
since comorbid depressive symptoms (but not the diagnosis 
of mood/anxiety disorders) may be relatively common in 
OCD; thus, studies on patients with these types of symptoms 
will be allowed. Concurrent personality disorders will not be 
a reason for exclusion, and diagnoses will have to be made 
through structured interviews.
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A concurrent pharmacological treatment will not be 
considered as a reason for exclusion. However, to control 
for the effects of a concurrent pharmacological treatment, 
the proportion of patients on psychotropic medications will 
be used as a moderator (see the “Coding of moderators” 
section). Studies on so-called treatment-resistant OCD will 
be included.
characteristics of interventions
Studies will be included if they assessed the efficacy of 
GCBT. GCBT is defined as a group psychotherapeutic treat-
ment mainly based on at least one of the following cognitive–
behavioral techniques: psychoeducation, ERP, and cognitive 
restructuring. Eligible studies will have to focus on GCBT as 
the main intervention. Thus, studies will not be included if 
GCBT is used exclusively as an augmentation strategy or an 
adjuvant component in the context of individual CBT.
characteristics of comparators
Studies will be included if they compared GCBT for OCD 
with a control condition (no treatment, waitlist), an active con-
trol condition (eg, treatment as usual or attention/relaxation 
controls), or individual CBT without group sessions.
characteristics of outcomes
Studies will be included if they used validated outcome 
measures of OCD symptoms, obsessive beliefs, anxiety, 
depression, quality of life and functioning, and satisfaction 
with treatment. Measures may be self-report instruments or 
interviews. Eligible outcomes will have to be measured at 
post-treatment at 1-month follow-up or longer. Studies will 
be screened for inclusion if they reported sufficient informa-
tion about the results to allow for effect size calculation. In 
cases where insufficient information is available from the 
paper, the authors will be contacted to provide additional 
information. Where no further data will be provided, studies 
will not be included.
characteristics of study/design
Studies will only be included if they used a RCT design, with 
random allocation to at least two conditions. Studies conducted 
on the same data of previously published trials will result in 
exclusion. No language restrictions will be applied.
Information sources  
and search procedure
The following search strategies will be used to identify stud-
ies for inclusion.
Electronic search
Studies will be retrieved through online systematic 
literature searches, in which keywords related to OCD 
(“obsessive compulsive disorder”, “obsessions”, “com-
pulsions”, “obsessive beliefs”, “anxiety disorder”) will 
be combined through the Boolean operator “AND” with 
keywords and text words indicative of GCBT construct 
(“group therapy”, “group treatment”, “group cognitive 
behavioural therapy”).
The following online databases will be searched: 
PsycINFO; PubMed; Science Direct; CINAHL; Biological 
Abstracts; PsycLIT; Embase; and the Cochrane Central Reg-
ister of Controlled Trials. No date restriction will be applied 
to the databases. The online search will be conducted on pub-
lished records from December 1966 to January 2014.15–18
corresponding authors
To request any further papers, either published or unpub-
lished, all the corresponding authors of the included studies 
will be contacted.
Hand-searching
Conference proceedings, doctoral theses, and dissertations 
will be hand-searched for the abstract books of the follow-
ing international associations relevant to the issue of OCD, 
occurring up to January 2014: European Association of 
Behavioural and Cognitive Therapies (EABCT), British 
Association of Behavioural and Cognitive Psychotherapy 
(BABCP), American Psychological Association (APA), 
Australian Association for Cognitive Behaviour Therapy 
(AACBT), and Association for Behavioral and Cognitive 
Therapies (ABCT).
An issue-by-issue examination of some relevant jour-
nals for this field from January 1990 to January 2014 
will be conducted. The following journals will be hand-
searched: American Journal of Psychiatry; Behaviour 
Research and Therapy; Behavior Therapy; Psychotherapy 
and Psychosomatics; Journal of Obsessive Compulsive 
and Related Disorders; Cognitive Behaviour Therapy; 
Journal of Behavior Therapy and Experimental Psychiatry; 
Psychological Medicine; Journal of Affective Disorders; 
Journal of Clinical Psychiatry; Journal of Clinical and 
Consulting Psychology.
Study selection
Studies will be assessed according to the eligibility criteria 
by two independent reviewers (AP and DD) during three dif-
ferent stages. During the first and the second stage, studies 
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will be examined with regard to the inclusion criteria after 
reading the title and abstract, respectively. During these 
stages, studies will be retained when there is no agreement 
on inclusion between the reviewers. Finally, the remaining 
studies will be assessed in terms of the eligibility criteria 
after the reading the full-text article. After each stage, the 
reviewers will discuss reasons for inclusion, and potential 
discrepancies in judgment will be addressed during meetings 
with an independent reviewer (GA) with the aim of obtain-
ing a shared pool of included studies for the meta-analysis. 
Between-reviewer agreement of study inclusion will be 
calculated by computing Cohen’s kappa index.19
Assessment of risk of bias
The methodological quality of the included RCTs will be 
assessed using the Cochrane Collaboration’s tool for risk of 
bias assessment.20 Two of the reviewers (AP and DD) will 
conduct the risk of bias assessments independently. Each 
discrepancy will be discussed and resolved in meetings. Each 
study will be rated for risks of bias owing to selection bias 
(random sequence generation and allocation concealment), 
detection bias (blinding of outcome assessment), attrition 
bias (incomplete outcome data), reporting bias (selective 
reporting), and other biases. Risk of bias due to blinding and 
incomplete outcome data will be separately assessed within 
each included study for different outcomes. Since the blind-
ing of participants can be critical in trials on the efficacy of 
psychotherapy, we did not use this item to assess the quality 
of RCTs on GCBT.
Risk of bias assessment will be conducted within each 
included trial and across the included trials. According to 
guidelines provided by Higgins and Green,20 each domain is 
rated as high, low, or unclear. For within-trial assessments, 
risk of bias will be classified as low if it is regarded as low 
by the two independent reviewers for all domains, it will 
be classified as unclear if it is regarded as low or unclear 
for all the domains, and it will be classified as high if it is 
regarded as high for one or more domains. For between-trial 
assessment, risk of bias will be classified as: 1) low, if most 
information is from trials at low risk of bias; 2) unclear, 
if most information is from trials at low or unclear risk of 
bias; and 3) high, if the proportion of information from tri-
als at high risk of bias is sufficient to affect interpretation 
of the results.20
coding of moderators
If the inconsistency analyses indicate large and significant 
heterogeneity between effect sizes, the role of the moderators 
will be investigated. Two independent reviewers (DD and AP) 
will code the moderators, extract the data from the primary 
studies, and insert them in an Excel worksheet. Subsequently, 
during meetings between the two reviewers, insertion of the 
data in the worksheets will be checked for accuracy, and each 
potential discrepancy will be discussed and resolved. The 
following variables will be coded as moderators:
1. Participants’ characteristics: 1) mean age of the sample; 
2) sex of the sample (coded as the percentage of female 
participants); 3) co-occurence of comorbid personality 
disorders (percentage of participants with comorbid 
personality disorders included in the sample); 4) OCD 
symptom severity (coded as a continuous variable 
based on the scores on the Yale–Brown Obsessive Com-
pulsive Scale [Y-BOCS]); 5) severity of concurrent 
depressive symptoms (coded as a continuous variable 
based on the scores on the Beck Depression Inventory 
[BDI]-II); 6) duration of OCD symptoms coded as the 
number of years from the first diagnosis of OCD made 
by a mental health professional, or as the age of onset 
self-reported by the patient; and 7) generational cohort 
(categorical variable: children/adolescent versus adult 
samples).
2. Treatment characteristics: 1) duration of treatment (coded 
as the number of weeks); 2) intensity of treatment (coded 
as the number of sessions per week and the number of 
treatment hours per week); and 3) proportion of patients 
on concurrent medication.
3. Study characteristics: 1) date of publication; 2) method-
ological quality (as a continuous variable based on the 
scores on the Cochrane Collaboration’s tool).
If these data are not reported in the paper, the authors of 
the study will be contacted to request the data.
Statistical analysis
Power calculations
An a priori power analysis was performed with the aim of 
investigating the number of studies requested to achieve 
statistically powerful analyses in order to identify a small 
effect size, as defined in Lipsey and Wilson.21 Power calcula-
tions were conducted according to the guidelines provided 
by Borenstein et al.22 Calculations suggested that we would 
need to include at least 20 studies with a mean sample size 
of 30 (15 participants per condition) to be able to detect an 
effect size of 0.30, assuming a medium-level study variance, 
a statistical power of 0.80, and a criterion for significance 
set at 0.05 (two-tailed test). Alternatively, we would need 15 
studies including 40 participants each, to detect an effect size 
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of 0.30. The power analysis was conducted using the Power 
and Precision software version 4.00.
data extraction and summary measures
Before calculating the effect sizes, potential outlier studies 
will be identified through the sample-adjusted meta-analytic 
deviance method.23
As we expect noticeable heterogeneity across the included 
studies, effect sizes will be calculated using a random-effects 
model. Random-effects models assume that the included 
studies are drawn from populations of studies that system-
atically differ from each other. According to these models, 
the effect sizes derived from included studies differ not 
only because of the random error within studies (as in the 
fixed-effects model), but also because of the true variation 
in effect sizes from one study to the other.23 Analyses will 
be conducted separately for studies comparing GCBT versus 
control conditions (no treatment or waitlist) for studies com-
paring GCBT versus active control conditions, and for studies 
comparing GCBT versus individual CBT.
The data requested for the calculation of the effect sizes 
(Hedges’ g)24 will be extracted independently by two meta-
analysts (DD and AP) through the following formula provided 
in Equation 1:
 Hedges’ ,g =
−M M
SD
GCBT Control (Individual CBT)
Pooled
 (1)
where M
GCBT
 is the mean of the groups of patients treated 
with GCBT, M
Control (Individual CBT)
 is the mean number of patients 
assigned to control conditions or individual CBT, and SD
Pooled
 
is the pooled standard deviation.
The effect size for each study will be weighted through 
the application of the following correction formula provided 
in Equation 2:
 W SEzr zr= 1 2/ ,
 
(2)
where SE2
zr
 is the standard error of the effect size computed 
for each study.
Effect sizes will be estimated using a 95% confidence 
interval and interpreted according to the criteria suggested by 
Cohen.19 Thus, effect sizes of 0.80 or more will be assumed 
to be large, 0.50 moderate, and 0.20 small.20 According to 
Hedges and Olkin,24 Hedges’ correction for small sample 
bias will be applied to all effect sizes.
A global effect size will be calculated as a mean 
effect size obtained by combining effect sizes related to 
all the considered outcomes. Effect sizes will be pooled 
for self-report instruments and interviews in a first phase. 
Subsequently, analyses will be performed separately for 
self-report instruments and then for interviews. In addition, 
effect sizes will be calculated separately as well for each of 
the aforementioned outcomes.
Inconsistency analysis
In order to assess between-studies heterogeneity, two comple-
mentary indices will be used: the I2 index21 and the Q statistic,24 
respectively. The I2 index determines, in percentage, the degree 
of heterogeneity in the effect sizes of the included studies.21 
A value approximating zero suggests homogeneity, whereas 
values of 25%–50%, 50%–75%, and 75%–100% represent 
low, medium, and large heterogeneity, respectively.21
Analysis of moderators
If the inconsistency analysis suggests large heterogeneity, an 
analysis of the aforementioned moderators will be conducted 
using a mixed-model analysis of variance and weighted least 
squares meta-regressions.
Publication bias
In order to investigate the likelihood that the effect sizes are 
subjected to publication bias, Orwin’s fail-safe N method25 
and a visual inspection of the funnel plot will be used.
Statistical analysis will be performed using the Power 
and Precision software version 4.00 and the Comprehensive 
Meta-Analysis software version 2.00 to conduct power cal-
culations and meta-analyses, respectively.
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